MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)
Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –
MeiraGTx total assets
Total assets on the balance sheet at the end of each period.
MeiraGTx's total assets was $396.45M at Jun 30, 2026. For fiscal 2025 it was $244.43M, down 9.4% from the year before. The highest annual figure on record is $363.70M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $244.43M | -9.4% |
| FY2024 | Dec 31, 2024 | $269.75M | -17.4% |
| FY2023 | Dec 31, 2023 | $326.74M | +2.7% |
| FY2022 | Dec 31, 2022 | $318.24M | -0.6% |
| FY2021 | Dec 31, 2021 | $320.16M | -12.0% |
| FY2020 | Dec 31, 2020 | $363.70M | +12.3% |
| FY2019 | Dec 31, 2019 | $323.89M | +234.3% |
| FY2018 | Dec 31, 2018 | $96.89M | +274.8% |
| FY2017 | Dec 31, 2017 | $25.85M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $396.45M | +99.5% |
| Q1 FY2026 | Mar 31, 2026 | $244.66M | +9.2% |
| Q4 FY2025 | Dec 31, 2025 | $244.43M | -9.4% |
| Q3 FY2025 | Sep 30, 2025 | $189.47M | -36.7% |
| Q2 FY2025 | Jun 30, 2025 | $198.72M | -25.5% |
| Q1 FY2025 | Mar 31, 2025 | $224.01M | -27.6% |
| Q4 FY2024 | Dec 31, 2024 | $269.75M | -17.4% |
| Q3 FY2024 | Sep 30, 2024 | $299.49M | +12.1% |
| Q2 FY2024 | Jun 30, 2024 | $266.65M | -14.1% |
| Q1 FY2024 | Mar 31, 2024 | $309.24M | +7.3% |
| Q4 FY2023 | Dec 31, 2023 | $326.74M | +2.7% |
| Q3 FY2023 | Sep 30, 2023 | $267.19M | -11.4% |
| Q2 FY2023 | Jun 30, 2023 | $310.26M | +22.9% |
| Q1 FY2023 | Mar 31, 2023 | $288.14M | +0.2% |
| Q4 FY2022 | Dec 31, 2022 | $318.24M | -0.6% |
| Q3 FY2022 | Sep 30, 2022 | $301.41M | -0.6% |
| Q2 FY2022 | Jun 30, 2022 | $252.46M | -22.7% |
| Q1 FY2022 | Mar 31, 2022 | $287.69M | -15.3% |
| Q4 FY2021 | Dec 31, 2021 | $320.16M | -12.0% |
| Q3 FY2021 | Sep 30, 2021 | $303.34M | +3.5% |
| Q2 FY2021 | Jun 30, 2021 | $326.77M | +12.4% |
| Q1 FY2021 | Mar 31, 2021 | $339.68M | +11.5% |
| Q4 FY2020 | Dec 31, 2020 | $363.70M | +12.3% |
| Q3 FY2020 | Sep 30, 2020 | $293.05M | -7.8% |
| Q2 FY2020 | Jun 30, 2020 | $290.61M | +14.8% |
| Q1 FY2020 | Mar 31, 2020 | $304.67M | +18.2% |
| Q4 FY2019 | Dec 31, 2019 | $323.89M | +234.3% |
| Q3 FY2019 | Sep 30, 2019 | $317.75M | +201.9% |
| Q2 FY2019 | Jun 30, 2019 | $253.08M | +115.1% |
| Q1 FY2019 | Mar 31, 2019 | $257.85M | +897.3% |
| Q4 FY2018 | Dec 31, 2018 | $96.89M | – |
| Q3 FY2018 | Sep 30, 2018 | $105.24M | – |
| Q2 FY2018 | Jun 30, 2018 | $117.68M | – |
| Q4 FY2017 | Dec 31, 2017 | $25.85M | – |
See a number that looks wrong?